A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys.
Cannabinoid-1 (CB(1)) receptor antagonists exhibit pharmacological properties favorable to treatment of obesity, caused by both centrally mediated effects on appetite and peripherally mediated effects on energy metabolism. However, the relative contribution of these effects to the weight loss produced by CB(1) receptor antagonists remains unclear. Here, we compare food intake-related and independent effects of the CB(1)-selective antagonist 1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-3-(methylamino) azetidine-3-carboxamide (PF-95453) in obese cynomolgus monkeys. Monkeys were divided into three study groups (n = 10 each) and treated once daily for 8 weeks with either vehicle or PF-95453 as follows: 1, fed ad libitum and dosed orally with vehicle; 2, fed ad libitum and dosed orally with PF-95453 (0.5 mg/kg weeks 1-3, 1.0 mg/kg weeks 4-8); and 3, fed an amount equal to the amount consumed by the drug-treated group and dosed orally with vehicle (pair-fed). PF-95453 treatment significantly reduced food consumption by 23%, body weight by 10%, body fat by 39%, and leptin by 34% while increasing adiponectin by 78% relative to vehicle-treated controls. Pair-fed animals did not exhibit reductions in body weight or leptin but did show significantly reduced body fat (11%) and increased adiponectin (15%) relative to vehicle-treated controls but markedly less than after PF-95453 treatment. Indeed, significant differences were noted between the drug-treated and pair-fed groups with respect to body weight reduction, body fat reduction, increased adiponectin, and leptin reduction. Similar to humans, monkeys treated with the CB(1) receptor antagonist exhibited decreased body weight and body fat, a substantial portion of which seemed to be independent of the effects on food intake.
Wagner
Janice D
JD
Department of Pathology, Wake Forest University, Winston-Salem, NC 27157, USA. jwagner@wfubmc.edu
Zhang
Li
L
Kavanagh
Kylie
K
Ward
Gina M
GM
Chin
Janice E
JE
Hadcock
John R
JR
Auerbach
Bruce J
BJ
Harwood
H James
HJ
D052242:Adiponectin / Q000378:metabolism; D050154:Adiposity / Q000187:drug effects*; D000818:Animals; D019440:Anti-Obesity Agents; D001384:Azetidines / Q000493:pharmacokinetics / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D001823:Body Composition / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D004032:Diet; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects / Q000502:physiology; D023381:Endpoint Determination; D005247:Feeding Behavior / Q000187:drug effects; D005951:Glucose Tolerance Test; D020738:Leptin / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008252:Macaca fascicularis; D008297:Male; D009765:Obesity / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D014227:Triazines / Q000493:pharmacokinetics / Q000494:pharmacology*; D015431:Weight Loss / Q000187:drug effects
C552955:1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo(1,5-a)(1,3,5)triazin-4-yl)-3-(methylamino)azetidine-3-carboxamide; D052242:Adiponectin; D019440:Anti-Obesity Agents; D001384:Azetidines; D001786:Blood Glucose; D020738:Leptin; D008055:Lipids; D043884:Receptor, Cannabinoid, CB1; D014227:Triazines